Predictive factors of a response to interferon therapy in chronic hepatitis C

Journal of Clinical Gastroenterology

Volumn 23, Issue 3, 1996, Pages 185-190

  Nomura, Hideyuki ^a,c   Kimura, Youichi ^a   Tada, Hitoshi ^a   Hisano, Chizuko ^a   Morita, Chika ^a   Okamoto, Osamu ^a   Shiraishi, Genji ^a   Kashiwagi, Seizaburo ^b  

^a Shin Kokura Hospital   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

^c Shin Kokura Hospital   (Japan)

Author keywords

Alanine aminotransferase; Hepatitis C; Hepatitis C virus; Histological activity index; Interferon ; RNA genotype; Treatment period; Virus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; INTERFERON; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; DOSE RESPONSE; FEMALE; GENOTYPE; HEART RATE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; TREATMENT PLANNING;

ADULT; ANTIVIRAL AGENTS; BASE SEQUENCE; CHRONIC DISEASE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; REGRESSION ANALYSIS; RNA, VIRAL;

EID: 0029955430     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-199610000-00006     Document Type: Article

References (41)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DM, Houghton M. Isolation of cDNA clone derived from a blood borne non-A non-B hepatitis genome. Science 1989;244:359-62.
2. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-4.
3. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A non-B hepatitis with recombinant human alpha interferon. N Engl J Med 1986;315:1575-8.
4. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alpha: a multi-center randomized, controlled trial. N Engl J Med 1989;321:1501-6.
5. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321:1506-10.
6. Kanai K, Iwata K, Nakao K, Kako M, Okamoto H. Suppression of hepatitis C virus RNA by interferon alpha. Lancet 1990;336:245.
7. Chayama K, Saitoh S, Arase Y, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991;13:1040-3.
8. Hagiwara H, Hayashi N, Mita E, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with Interferon-α. Hepatology 1992;15:37-41.
9. Castilla A, Camps-Bansell J, Civeira MP, Prieto J. Lymphoblastoid alpha interferon for chronic hepatitis C: a randomized controlled study. Am J Gastroenterol 1993;88:233-9.
10. Hagiwara H, Hayashi N, Mita E, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology 1993;104:877-83.
11. Di Bisceglie A, Hoofnagle JH. Therapy of chronic hepatitis C with alpha-interferon: the answer? or more questions? Hepatology 1991;13:601-3.
12. Camps J, Crisostomo S, Garcia-Granero M, Riezu-Boj JI, Civeira MP, Prieto J. Prediction of the response of chronic hepatitis C to interferon alpha: a statistical analysis of pretreatment variables. Gut 1993;34:1714-7.
13. Tsubota A, Chayama K, Arase Y, et al. Factors useful in predicting the response to interferon therapy in chronic hepatitis C. J Gastroenterol Hepatol 1993;8:535-9.
14. Yamada G, Takahashi M, Tsuji T, Yoshizawa H, Okamoto H. Quantitative HCV-RNA and effect of interferon therapy in chronic hepatitis C. Dig Dis Sci 1992;37:1926-7.
15. Hino K, Sainokami S, Shimoda K, et al. Genotypes and titers of hepatitis C virus for predicting response to Interferon in patients with chronic hepatitis C. J Med Virol 1994;42:299-305.
16. Hayashi J, Ohmiya M, Kishihara Y, et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 1994;89:2151-6.
17. Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992;339:1543.
18. Yoshioka K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon alpha therapy: relation to genotypes of hepatitis C virus. Hepatology 1992;16:293-9.
19. Martnot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050-6.
20. Conjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1326-9.
21. Yamada G, Takatani M, Kishi F, et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995;22:1351-4.
22. Aiyama T, Yoshioka K, Takayanagi M, Iwata K, Okumura A, Kakumu S. Serum HCV RNA titer at the end of interferon therapy predicts the long term outcome of treatment. J Hepatol 1995;23:497-502.
23. Yuki N, Hayashi N, Kasahara A, et al. Pretreatment viral load and response to prolonged Interteron-α course for chronic hepatitis C. J Hepatol 1995;22:457-63.
24. Marcellin P, Pouteau M, Martinot-Peignoux M, et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995;109:156-65.
25. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332: 1457-62.
26. Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995;22:700-6.
27. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Inter-feron alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. J Hepatol 1995;23:487-96.
28. Fong TL, Morgan TR, Phan CG, Hoefs JC. Raising the dose of interferon does not improve the response in chronic hepatitis C. J Clin Gastroenterol 1995;20:42-4.
29. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
30. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73:673-9.
31. Okamoto H, Kurai K, Okada S, et al. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four district genotypes. Virology 1992;188:331-41.
32. Simmonds P, Alberti A, Alter HJ, et al. A propose system for the nomenclature of hepatitis C virus genotypes. Hepatology 1994;19:1321-4.
33. Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21:570-83.
34. Lau JYN, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-4.
35. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferon in cancer patients. J Clin Oncol 1986;4:234.
36. Sunderkotter C, Luger T, Kolde G. Severe hypertriglyceridaemia and interferon-α. Lancet 1993;342:1111-2.
37. Hisawa N, Kojima J, Kojima T, et al. A patient with chronic hepatitis C who simultaneously developed interstitial pneumonia, hemolytic anemia and cholestatic liver dysfunction after alpha-interferon administration. Intern Med 1994;33:337-41.
38. Kodama T, Hohami S, Kamijou K, et al. Development of transient thyroid disease and reaction during treatment of chronic hepatitis C with interferon. J Gastroenterol 1994;29: 289-92.
39. Sugano S, Yanagimoto M, Suzuki T, et al. Retinal complications with elevated circulating plasma C5a associated with Imerferon-α therapy for chronic active hepatitis C Am J Gastroenterol 1994;89:2054-6.
40. Uchida K, Matsui A, Nakano S, Kigoshi T, Morimoto S. Painless thyroiditis occurring during long-term treatment with inter-feron alfa in a patient with chronic active hepatitis C. South Med J 1996;89:81-3.
41. Bonkovsky HL, Clifford BD, Smith U, Allan C, Banner B. High-dose Interferon-α 2b for retreatment of nonresponders or relapsing patients with chronic hepatitis C, A controlled randomized trial. Dig Dis Sci 1996;41:149-54.